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Abstract Human class III alcohol dehydrogenase (ADH3),
also known as glutathione-dependent formaldehyde dehydroge-
nase, exhibited non-hyperbolic kinetics with ethanol at a near
physiological pH 7.5. The S0:5 and kcat were determined to be
3.4& 0.3 M and 33& 3 min31, and the Hill coe⁄cient (h)
2.21& 0.09, indicating positive cooperativity. Strikingly, the
S0:5 for ethanol was found to be 5.4U106-fold higher than the
Km for S-(hydroxymethyl)glutathione, a classic substrate for the
enzyme, whereas the kcat for the former was 41% lower than
that for the latter. Isotope e¡ects on enzyme activity suggest
that hydride transfer may be rate-limiting in the oxidation of
ethanol. Kinetic simulations using the experimentally deter-
mined Hill constant suggest that gastric ADH3 may highly
e¡ectively contribute to the ¢rst-pass metabolism at 0.5^3 M
ethanol, an attainable range in the gastric lumen during alcohol
consumption. The positive cooperativity mainly accounts for this
metabolic role of ADH3.
5 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Alcohol dehydrogenase (ADH) constitutes a complex en-
zyme family [1,2]. Class III ADH (ADH3) is unique in its
ancient origin [3], identi¢cation as a glutathione-dependent
formaldehyde dehydrogenase [4] and as a constant type with
regard to enzyme function and overall structure [5]. Expres-
sion of ADH3 appears ubiquitous in mammalian tissues [6].
ADH3 is highly active toward a wide variety of substrates,
notably S-(hydroxymethyl)glutathione (HMGSH) [4], S-nitro-
soglutathione [7,8], g-hydroxyfatty acids [9], and 20-hydroxy-
leukotriene B4 [10]. Recent studies with the gene knocked
out in mice support that ADH3 may contribute to detoxi¢ca-
tion of formaldehyde [11], protection against nitrosative
stress, and the maintenance of S-nitrosothiol homeostasis
[12] that appears central to nitric oxide signaling and host
defense. Despite its extremely poor activity with all-trans-ret-
inol, ADH3 may also be involved in the production of reti-
noic acid, a morphogen and transcriptional regulator, as re-
vealed from the ADH33=3 mice studies [13].
Human ADH3 oxidizes ethanol very poorly at physiologi-
cally attainable blood alcohol levels (6 50 mM) and the ac-
tivity appeared directly proportional to the substrate concen-
tration up to 2 M ethanol at alkaline pH [9,14,15]. It has thus
been long thought that ADH3 plays only a very minor role in
the hepatic metabolism of ethanol [16]. First-pass, or presys-
temic, metabolism (FPM) of alcohol in stomach, however,
presents a unique situation since the gastric ethanol levels
can reach virtually molar range during alcohol consumption
[17]. A recent study [18] correlating ethanol pharmacokinetics
in blood and ADH3 activity in stomach suggested that the
gastric enzyme may contribute to the FPM in humans. We
previously demonstrated by kinetic simulation that at near
physiological pH the high-Km members of the human ADH
family, ADH2 in liver and ADH4 in stomach, may e¡ectively
contribute to the FPM [19]. FPM of alcohol in£uences its
bioavailability in the systemic blood and hence the pharma-
codynamic e¡ects on the target tissues. We report here for the
¢rst time that human ADH3 exhibits positive cooperativity
with ethanol and the metabolic signi¢cance in FPM by kinetic
simulation.
2. Materials and methods
Human recombinant ADH3 was expressed in Escherichia coli as
described previously [20]. The resulting enzyme was initially isolated
from the lysate supernatant by DEAE-cellulose chromatography
(DE52, Whatman; 150 ml of DEAE/l of culture) in 10 mM Tris,
pH 8.0, 0.1% (v/v) 2-mercaptoethanol at 4‡C. The unbound proteins
were eluted o¡ the 2.6U28-cm DEAE-cellulose column with the equi-
librating bu¡er. The eluate was concentrated and then dialyzed into
50 mM sodium phosphate, pH 7.4, 0.1% 2-mercaptoethanol and
loaded onto a 1.6U10-cm 5P-AMP-Sepharose (Amersham Bioscien-
ces) column equilibrated in the same bu¡er. The protein was eluted
with a linear gradient from 0 to 1 mM NADH in 50 mM sodium
phosphate, pH 7.4, 0.1% 2-mercaptoethanol. The isolated recombi-
nant enzyme exhibited a single protein-staining band with a molecular
mass of 40 kDa on sodium dodecyl sulfate^polyacrylamide gel elec-
trophoresis by a PhastSystem according to the manufacturer’s proto-
col (Amersham Biosciences). Total protein concentration was deter-
mined by the Lowry method [21]. ADH3 (s 1 mg/ml) appeared stable
for at least 5 days in 10 mM sodium phosphate, pH 7.5, when it was
kept in an ice bath.
Formaldehyde was prepared by hydrolyzing hexamethylenetet-
ramine with sulfuric acid and standardized after steam distillation by
the chromotropic acid method as described previously [22]. During
activity measurements, glutathione and formaldehyde were allowed to
reach equilibrium with the hemithioacetal adduct HMGSH for 2 min
in assay bu¡er (pH 7.5) at 25‡C before addition of the remaining
components to initiate the assay. The concentration of HMGSH in
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the assay mixture was calculated using a Keq of 1.77 mM31 [20]. Due
to very low Michaelis constant (6 1 WM) for HMGSH, enzyme ac-
tivity was measured by monitoring £uorescence of the produced
NADH (excitation at 340 nm; emission at 460 nm) in the Km deter-
mination experiments. Enzyme activity with ethanol was assayed by
monitoring the production of NADH at 340 nm using an A340 of 6.22
mM31 cm31. The reaction was initiated with addition of the enzyme.
Stability of ADH3 with ethanol in 100 mM sodium phosphate at pH
7.5 and 25‡C was examined for a duration of 2^3 min that was
required in the linear initial velocity measurements and the reaction
was then initiated with addition of the coenzyme NADþ. Controls for
the examined ethanol concentrations were those in the absence of
incubation with the enzyme, i.e. reaction mixture of the substrate
and coenzyme was directly initiated with addition of the enzyme,
and the linear initial velocity was measured. The ethanol concentra-
tion up to 3.4 M was found with reasonable stability (s 90% activity)
and thus was employed as the upper limit in experiments of substrate
saturation.
Kinetic studies with ethanol and HMGSH were performed in 100
mM sodium phosphate (pH 7.5) at 25‡C containing 0.5 mM NADþ
and varied concentrations of substrate. It has been reported that
cytosolic NADþ concentration in rat hepatocytes was ca. 0.5 mM
[35]. Steady-state kinetic data were analyzed by non-linear regression
using the programs of Cleland [23] or the formulating equations that
were written according to the statistical package program of Sigma-
Plot (version 7.0). Initial velocity data were ¢t with the Michaelis^
Menten equation (Eq. 1) or the Hill exponential equation (Eq. 2).
v ¼ VmaxUS
Km þ S ð1Þ
v ¼ VmaxUS
n
Sn0:5 þ Sn
ð2Þ
where Vmax is the maximum velocity; S is the substrate concentration;
Km is the Michaelis constant; S0:5 is the substrate concentration at
half-maximal velocity; and n is the Hill coe⁄cient (also denoted h).
Maximal velocity is expressed as turnover number (min31) based on a
subunit molecular mass of 40 kDa. To visualize kinetic cooperativity,
initial velocity data were also ¢t with equations for the Hanes plot
(Eq. 3) and the Hill plot (Eq. 4).
S
v
¼ S
Vmax
þ Km
Vmax
ð3Þ
log
v
Vmax3v
¼ nUlogS3nUlogS0:5 ð4Þ
FPM of ethanol by ADH3 in the stomach and liver was simulated
using a combination of two Hill exponential equations for two sub-
strate concentrations at di¡erent compartments.
FPM ¼ VmaxUS
n
1
Sn0:5 þ Sn1
3
VmaxUSn2
Sn0:5 þ Sn2
ð5Þ
where S1 is the ethanol concentration in the gastric lumen or the
portal vein and S2 is the ethanol concentration in the systemic blood.
All of the kinetic measurements were run in duplicate for HMGSH
and in triplicate for ethanol. The values represent the meansPS.E.M.
3. Results
Substrate saturation pro¢les of human ADH3 displayed
Michaelian kinetics with the classic substrate HMGSH but
non-hyperbolic kinetics with ethanol at pH 7.5 (Fig. 1). The
Hanes plots show a straight line with positive slope for
HMGSH (Fig. 1B) and a concave-up curvature for ethanol
(Fig. 1A) that is typical of positive cooperativity [24]. Both
substrates ¢t well to the linear Hill plot over the entire con-
centration range (regression coe⁄cient R2s 0.99) (Fig. 2).
The kinetic parameters for ethanol and HMGSH of ADH3
are compared in Table 1. Standard errors for all determined
kinetic parameters were less than 10% of the values, suggest-
ing a reasonable precision. Strikingly, the S0:5 for ethanol was
5.4U106-fold higher than the Km for HMGSH, whereas the
kcat for the former was 41% lower than that for the latter. The
Hill coe⁄cient, h, for ethanol oxidation was determined to be
2.21P 0.09, clearly indicating a positive cooperativity. Kinetic
measurements for ethanol were also performed at a higher
NADþ (5 mM) in the same bu¡er, and kcat and S0:5 were
determined to be 28P 2 min31 and 3.0P 0.2 M, and h
2.26P 0.11. The kinetic parameters for ethanol were similar
at 0.5 and 5 mM NADþ. It was attempted to study kinetic
isotope e¡ects for ethanol at 0.5 mM NADþ. The kcat and S0:5
for deuterio ethanol failed to show acceptable statistical pre-
cision as ¢tting the data to Eq. 2, though it still exhibited a
reliable positive cooperativity of h=1.93P 0.05. This may be
in part due to much lower enzyme activity with deuterio etha-
nol compared with protio ethanol in the paired assays. The
activity ratio pro¢le of protio ethanol to deuterio ethanol
showed that vH=D ranged over 5.1^3.3 for 0.86^3.4 M sub-
strate, demonstrating a signi¢cant isotope e¡ect on the en-
zyme activity (Fig. 3).
FMP of ethanol through the ADH3 pathway in human
stomach and liver was quantitatively assessed using Eq. 5
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Fig. 1. Saturation pro¢les of ADH3 toward oxidation of ethanol
(A) and HMGSH (B). Enzyme activity was determined in 0.1 M so-
dium phosphate, pH 7.5, at 25‡C, containing 0.5 mM NADþ. Spe-
ci¢c activity is measured as Wmol/min/mg (U/mg). The lines are the
¢t of data to Eqs. 2 and 1 in A and B, respectively. Inset is the
data ¢t to Eq. 3. The Hill coe⁄cient, h, for ethanol was calculated
to be 2.21P 0.09.
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on the basis of a reasonable estimation of the enzyme contents
in the tissues as well as blood ethanol levels in di¡erent com-
partments. It was reported following puri¢cation and the cor-
rection for the yield that human liver contained V20 mg
ADH3 per 100 g tissue [15]. Hence the content of ADH3 in
a liver (V1500 g) was estimated as 300 mg. Based on previous
reports for the speci¢c activity of ADH3 in human stomach
mucosa (V6 nmol/min/mg mucosal protein) [18], the protein
concentration of the human stomach mucosa (V60 mg/g tis-
sue) [25], and the speci¢c activity of the puri¢ed ADH3 which
was measured according to the assay condition in [18] (i.e. 1.6
Wmol/min/mg; unpublished data), it was estimated that hu-
man stomach mucosa containedV0.2 mg ADH3 per g tissue.
Hence the ADH3 content in the mucosa of the stomach (as-
suming one third of the stomach is mucosa, i.e. 50 g) can be
estimated as 10 mg. The capacity of FPM by ADH3 in stom-
ach and liver was then simulated using Eq. 5 (Table 2). Tre-
mendous rises of the enzyme activity (7600^180 000-fold) in
comparison with the corresponding substrate concentration
ratios (75^250) demonstrated that gastric ADH3 may e¡ec-
tively contribute to FPM of ethanol on account of the positive
cooperativity.
4. Discussion
Human ADH3 exhibits hyperbolic saturation kinetics to-
ward a wide range (0.7^50 Km) of HMGSH (Fig. 1B). This
¢nding is in agreement with the report by Sanghani et al. [20]
but in con£ict with that by Uotila and Mannervik [27] who
observed a non-hyperbolic behavior. Steady-state kinetic and
equilibrium binding studies indicate that the oxidation of
HMGSH with human ADH3 is consistent with a rapid equi-
librium random sequential mechanism [20]. The structural ex-
planation for the mechanism has been ascribed to a semi-open
structure of the substrate/coenzyme domain [28]. In contrast,
human ADH3 displays a non-hyperbolic saturation kinetics
toward the far smaller substrate ethanol at pH 7.5 (Fig. 1A)
with a positive cooperativity of h=2.2 (Table 1). Previous
studies [9,14,15] based on the observations of a linear satura-
tion pro¢le up to 2 M ethanol and the corresponding linear
double reciprocal plot suggested that human ADH3 may fol-
low the Michaelian kinetics with ethanol at alkaline pH 10.
The kcat and Km for ethanol could not be determined in these
studies simply because of a presumed extremely high Km
[9,15]. In the present study at pH 7.5, the kcat and S0:5 for
ethanol of ADH3 were determined to be 33 min31 and 3.4 M,
respectively (Table 1). The S0:5 is strikingly 100^150 000-fold
greater than the Kms for human ADH1A, ADH1B1,
ADH1B2, ADH1C1, ADH2 and ADH4 [19]. The kcat is
1.3^8.7-fold higher than those of the ADH1A, ADH1B1,
ADH1C1 and ADH2, but 7.3- and 45-fold lower than those
of the ADH1B2 and ADH4, respectively [19]. ADH1B2 and
ADH4 belong to the high-kcat members of the family [29].
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Fig. 2. Hill plots for ethanol (A) and HMGSH (B). The line is the
linear regression of data to Eq. 4. The regression coe⁄cients, R2,
are 0.997 and 0.992 for ethanol and HMGSH, respectively. The Hill
coe⁄cient, h, for HMGSH was calculated to be 1.01P0.03.
Table 1
Kinetic parameters of ADH3 at pH 7.5
Substrate Kinetic parameter
Ethanol S0:5 (M) 3.4P 0.3
kcat (min31) 33P 3
h 2.21P0.09
HMGSH Km (WM) 0.63P0.03
kcat (min31) 56P 1
kcat/Km (min31 WM31) 89P 3
h 1.01P0.03
For experimental conditions and the ¢tting equations, see Figs. 1
and 2. h, Hill coe⁄cient. Values represent meansPS.E.M.
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Fig. 3. Deuterium isotope e¡ects for the ethanol-oxidizing activity.
vH=D represents ratios of the mean activity of protio ethanol to that
of deuterio ethanol (ethanol-d5). Activity measurements were run in
triplicate for each concentration point. The linear equation of best
¢t for the data was estimated to be y=30.627x+5.416; R2 = 0.905.
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Therefore, the kinetic features for ethanol oxidation for
ADH3 in the human ADH family are a tremendously large
S0:5, and the highest kcat among the member group with lower
catalytic constants.
Human ADH1C1 and ADH1C2 allozymes exhibit a nega-
tive cooperativity toward ethanol oxidation [19,30]. This has
been explained by an ordered sequential mechanism with al-
ternative pathways, including abortive enzyme^NADH^etha-
nol and binary enzyme^NADH complexes, which di¡er in the
rate of dissociation of NADH [31]. The NADH release ap-
pears to be rate-limiting in ethanol oxidation for most mam-
malian ADHs such as the prototype horse ADH1E [32]. In
contrast, human ADH3 exhibits positive cooperativity with
ethanol. It seems unlikely through the same mechanism of
alternative pathways for coenzyme dissociation which deter-
mines the catalytic rate. Deuterium isotope e¡ect results (Fig.
3) suggest that hydride transfer rather than coenzyme release
may be rate-limiting for ethanol oxidation. This inference is
supported by the ¢nding that kcat for ethanol appears to be
even lower than that for HMGSH (Table 1) and that the
conversion of central ternary complexes is rate-limiting in
HMGSH oxidation for human ADH3, consistent with a rapid
equilibrium random mechanism [20]. X-ray studies [28,33]
provide no evidence of a subunit interaction in human
ADH3 resulting from binding with the substrate ligand which
would account for a site^site cooperativity. Kinetic studies of
homodimer and the heterodimer of human ADH1B1 and
ADH1B2 allozymes indicate that the constituent subunits
act independently [34]. To examine a possible steady-state
random mechanism [24] that might cause the observed kinetic
cooperativity at 0.5 mM NADþ (Fig. 1A), ethanol saturation
kinetics was also performed in the presence of 5 mM NADþ
(i.e. 455-fold greater than the Kd [20] for the enzyme^NADþ
complex). This potential kinetic cause seems to be ruled out
by the ¢nding of the very similar kinetic parameters (i.e. S0:5,
kcat and h) for ethanol that were determined at 0.5 and 5 mM
NADþ, since under such a huge excess of coenzyme (5 mM)
the path of binding NADþ prior to ethanol should be pre-
dominant, i.e. the reaction would become ordered for a ran-
dom mechanism [24]. The exact kinetic mechanism of ADH3
for ethanol remains unclear. It was di⁄cult to approach using
initial velocity study owing to the fairly low activity with such
a high S0:5 enzyme in the experiments. We speculate that one
possible explanation would be binding of multiple ethanol
molecules in the relatively spacious active site as alternative
pathways when increasing ethanol concentration that could
facilitate to yield a binding mode better for hydride transfer
in the enzyme^NADþ^ethanol complex. It obviously requires
further studies to test this hypothetical mechanism for the
observed kinetic cooperativity.
FPM, i.e. the di¡erence between the quantity of ethanol
that reaches the systemic circulation by the intravenous route
and the quantity that entered by the oral dose, may mainly
occur in the liver and stomach. The contribution of gastric
and hepatic ADH3 to the FPM can be simulated using Eq. 5
(Table 2). The simulation results demonstrate that the very
high S0:5 (3.4 M) in combination with a quite high h (2.2)
contributes to a surprisingly signi¢cant FPM at the range of
0.5^3 M ethanol that is attainable in the gastric lumen during
alcohol consumption. This is evidenced by a striking contrast
of the activity increase folds with the corresponding concen-
tration ratios of ethanol. For instance, ADH3 exhibits a huge
increase of activity (180 000-fold) at ethanol levels of 1000
mM in the gastric lumen versus 4 mM in the systemic blood
(cf. 250, the corresponding ethanol concentration ratio). Thus
a 720-fold (180 0006250= 720) activity increase is mainly at-
tributable to the positive cooperativity for ethanol oxidation.
The capacity of hepatic FPM through ADH3 appears much
lower than that in the stomach (Table 2). This is because of
the much lower ethanol levels in portal vein than in gastric
lumen even though the hepatic ADH3 content is estimated to
be 30-fold greater than the gastric enzyme. It is worth noting,
however, that the amount of FPM contributed by both gastric
and hepatic ADH3 (e.g. 1-h average FPM capacity for an
ethanol dose of 0.3 g/kg or 4-h average FPM capacity for
1.75 g/kg in a 70-kg person) may be very minor (calculated
estimate, 6 0.1%) relative to the total amount of ethanol con-
sumed. It thus seems unlikely that the gender di¡erence in
postprandial blood ethanol levels is due mainly to the di¡er-
ence in gastric ADH3 activity as proposed by Baraona et al.
[18].
In conclusion, human ADH3 exhibits non-hyperbolic satu-
ration kinetics with ethanol at near physiological pH. The
high S0:5 and in particular the relatively high h account for
the e¡ective contribution to FPM by gastric ADH3 at phys-
iologically attainable ethanol levels.
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Table 2
Simulations of gastric and hepatic contribution to FPM of ethanol by ADH3
Organ Assumed ethanol concentration Activity increase
(fold)
FPM capacity
(Wmol/min/organ)
Gastric lumen
(mM)
Portal vein
(mM)
Systemic blood
(mM)
Concentration ratio
Stomach 500 4 125 40 000 0.12
1000 4 250 180 000 0.52
3000 40 75 7 600 3.6
Liver 50 4 12.5 260 0.023
200 40 5 34 0.47
Enzyme activity was simulated using Eq. 2 and the capacity for FPM was simulated using Eq. 5. For values of the kinetic parameters, see Ta-
ble 1. Total contents of ADH3 were estimated as 10 mg in the stomach and 300 mg in the liver (see Section 3). It was reported that in humans
the blood ethanol levels may reach V4 mM during 30^90 min after postprandial ingestion of alcohol (0.3 g/kg) [18] and may reach V40 mM
during 2^8 h after ingestion (1.75 g/kg) [26]. Ethanol levels in the human gastric lumen may reach V1.5 M after ingestion (0.8 g/kg) [17]. 3 M
ethanol is equivalent to 17.5% (v/v). The cytosolic NADþ concentration in rat liver was reported to be V0.5 mM [35].
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